These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28972083)

  • 1. Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials.
    Koster BD; van den Hout MFCM; Sluijter BJR; Molenkamp BG; Vuylsteke RJCLM; Baars A; van Leeuwen PAM; Scheper RJ; Petrousjka van den Tol M; van den Eertwegh AJM; de Gruijl TD
    Clin Cancer Res; 2017 Oct; 23(19):5679-5686. PubMed ID: 28972083
    [No Abstract]   [Full Text] [Related]  

  • 2. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
    van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
    Eggermont AM; Chiarion-Sileni V; Grob JJ; Dummer R; Wolchok JD; Schmidt H; Hamid O; Robert C; Ascierto PA; Richards JM; Lebbé C; Ferraresi V; Smylie M; Weber JS; Maio M; Konto C; Hoos A; de Pril V; Gurunath RK; de Schaetzen G; Suciu S; Testori A
    Lancet Oncol; 2015 May; 16(5):522-30. PubMed ID: 25840693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients.
    Molenkamp BG; van Leeuwen PA; Meijer S; Sluijter BJ; Wijnands PG; Baars A; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2007 May; 13(10):2961-9. PubMed ID: 17504997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell infiltration on local CpG-B delivery in early-stage melanoma is predominantly related to CLEC9A
    Koster BD; López González M; van den Hout MF; Turksma AW; Sluijter BJ; Molenkamp BG; van Leeuwen PA; Vosslamber S; Scheper RJ; van den Eertwegh AJ; van den Tol MP; Jordanova EJ; de Gruijl TD
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
    Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arming the Melanoma Sentinel Lymph Node through Local Administration of CpG-B and GM-CSF: Recruitment and Activation of BDCA3/CD141(+) Dendritic Cells and Enhanced Cross-Presentation.
    Sluijter BJ; van den Hout MF; Koster BD; van Leeuwen PA; Schneiders FL; van de Ven R; Molenkamp BG; Vosslamber S; Verweij CL; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Cancer Immunol Res; 2015 May; 3(5):495-505. PubMed ID: 25633713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.
    Gershenwald JE; Colome MI; Lee JE; Mansfield PF; Tseng C; Lee JJ; Balch CM; Ross MI
    J Clin Oncol; 1998 Jun; 16(6):2253-60. PubMed ID: 9626228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic flow is mostly preserved after sentinel lymph node biopsy in primary cutaneous malignant melanoma.
    Yokota K; Sawada M; Matsumoto T; Hasegawa Y; Kono M; Akiyama M
    J Dermatol Sci; 2015 May; 78(2):101-7. PubMed ID: 25771166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
    Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
    Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
    McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
    J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observation after a positive sentinel lymph node biopsy in patients with melanoma.
    Bamboat ZM; Konstantinidis IT; Kuk D; Ariyan CE; Brady MS; Coit DG
    Ann Surg Oncol; 2014 Sep; 21(9):3117-23. PubMed ID: 24833100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.
    Speijers MJ; Bastiaannet E; Sloot S; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2015 Sep; 22(9):2978-87. PubMed ID: 25605514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of recurrence in patients with melanoma and histologically negative but RT-PCR-positive sentinel lymph nodes.
    Goydos JS; Patel KN; Shih WJ; Lu SE; Yudd AP; Kempf JS; Bancila E; Germino FJ
    J Am Coll Surg; 2003 Feb; 196(2):196-204; discussion 204-5. PubMed ID: 12595045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes.
    Egger ME; Bhutiani N; Farmer RW; Stromberg AJ; Martin RC; Quillo AR; McMasters KM; Scoggins CR
    Surgery; 2016 May; 159(5):1412-21. PubMed ID: 26775577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma.
    Gipponi M; Solari N; Giovinazzo D; Queirolo P; Bertoglio S; Villa G; Gualco M; Bleidl D; Cafiero F
    Anticancer Res; 2014 Jun; 34(6):3197-203. PubMed ID: 24922694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
    Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
    Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of first-recurrence and post-recurrence survival in patients with primary cutaneous melanoma after sentinel lymph node biopsy.
    Dalal KM; Patel A; Brady MS; Jaques DP; Coit DG
    Ann Surg Oncol; 2007 Jun; 14(6):1934-42. PubMed ID: 17406951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.
    Molenkamp BG; Sluijter BJ; van Leeuwen PA; Santegoets SJ; Meijer S; Wijnands PG; Haanen JB; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
    Clin Cancer Res; 2008 Jul; 14(14):4532-42. PubMed ID: 18628468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.